早期不同剂量阿托伐他汀对急性冠状动脉综合征患者斑块稳定性的影响  

The effects of early different dose of atorvastatin therapy on plaque stability in patients with acute coronary syndrome

作　　者：王志强[1] 曹东来[1] 韩冷[1] 郑建良[1] 何俊[1] 

机构地区：[1]江苏省常熟市第一人民医院心内科,215500

出　　处：《临床合理用药杂志》2011年第1期4-5,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察早期应用不同剂量阿托伐他汀对急性冠状动脉综合征(ACS)患者稳定斑块、减少炎性反应的影响。方法 将69例ACS患者(ACS组)随机分为小剂量亚组(给予阿托伐他汀10mg/d)35例、大剂量亚组(给予阿托伐他汀40mg/d)34例,并设正常对照组(同期健康查体者)34例。于治疗前和治疗2周后分别测定并比较血清可溶性白细胞分化抗原配体40(sCD40L)、基质金属蛋白酶-9(MMP-9)、高敏C-反应蛋白(hs-CRP)水平。结果 治疗前ACS组血清sCD40L、MMP-9、hs-CRP水平均较对照组明显增高(P<0.01)。ACS组在治疗后sCD40L、MMP-9、和hs-CRP水平均有明显降低(P<0.01),但大剂量亚组较小剂量亚组降低幅度更大(P<0.05)。结论 早期应用大剂量阿托伐他汀治疗ACS,能明显降低患者血清炎性因子水平,减少炎性反应,具有稳定斑块的作用。Objective To explore the effects of early different dose of atorvastatin therapy on plaque stability in patients with acute coronary syndrome（ACS）.Methods 69 cases patients with ACS（ACS group）were randomly divided into two groups,which were given atorvastatin 10mg/d（low-dose group,n=35）,and 40mg/d（high-dose group,n=34）.34 healthy peoples were taken as control group.Before and after treatment of two weeks,measured the levels of serum sCD40L、MMP-9 and hs-CRP of 3 groups.Results Before treatment,the levels of serum sCD40L、MMP-9 and hs-CRP were significantly higher than that in control group（P0.01）.After treatment,the levels of serum sCD40L、MMP-9 and hs-CRP of ACS group were reduced（P0.01）,but which was more reduced in high-dose group than in low-dose group（P0.05）.Conclusion Early high-dose of atorvastatin in ACS can significantly reduce serum levels of inflammatory cytokines,reduce the inflammatory response,has on effect of stable plaque.

关 键 词：阿托伐他汀 冠状动脉综合征 急性 可溶性白细胞分化抗原40配体 基质金属蛋白酶-9 高敏C-反应蛋白 

分 类 号：R541.4[医药卫生—心血管疾病]